CLAIMS

1. A compound selected from the group consisting of:

2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzoic acid

(R)-N-((3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)-5-phenylpentanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)-4-phenylbutanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-methoxyphenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-methoxyphenyl)furan-2-carboxamide

(R)-5-(3-cyanophenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-hydroxyphenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(5-methoxypyridin-3-yl)furan-2-carboxamide

(R)-5-(4-cyanophenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-sulfamoylphenyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(trifluoromethoxy)phenyl)furan-2-carboxamide

(R)-5-(3-ethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(6-methoxypyridin-2-yl)furan-2-carboxamide

(R)-methyl 3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate

(R)-5-(4-fluoro-3-methoxyphenyl)-N-((2-((N-

hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(4-methoxypyridin-2-yl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(methylcarbamoyl)phenyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)-4-phenylbutanamido)methyl)-5-(3-(methylsulfonyl)phenyl)furan-2-carboxamide
(R)-5-(3-(N,N-dimethylsulfamoyl)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(N-methylsulfamoyl)phenyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(2,2,2-trifluoroethoxy)phenyl)furan-2-carboxamide
N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-isopropoxyphenyl)furan-2-carboxamide
(R)-methyl 3-ethoxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate
(R)-5-(3-(dimethylamino)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(N-propionylsulfamoyl)phenyl)furan-2-carboxamide
(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-methoxybenzoic acid
(R)-3-ethoxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
ethyl (3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)(methyl)phosphinate
N-(((R)-2-((S)-2-hydroxy-1-(N-hydroxyformamido)ethyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide
(R)-5-(3-((2-aminoethyl)carbamoyl)-5-methoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(3-((2-aminoethyl)carbamoyl)-5-ethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-5-(3-(difluoromethoxy)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-dimethyl (3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonate

(R)-5-(1,1-dioxido-2,3-dihydrobenzo[d]isothiazol-6-yl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(2-(pyrrolidin-1-yl)ethoxy)phenyl)furan-2-carboxamide

3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoic acid

5-(3-((2-aminoethyl)carbamoyl)-5-ethoxyphenyl)-N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide

2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid

2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid

2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2-methylpropanoic acid

1-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)cyclopropanecarboxylic acid

(S)-5-(tert-butoxy)-4-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl) heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-5-oxopentanoic acid

5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)nicotinic acid

(S)-4-(tert-butoxy)-3-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-4-oxobutanoic acid

(S)-dimethyl 2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)pentanedioate

2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2,2-difluoroacetic acid

dimethyl (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonate

(R)-methyl 2-fluoro-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoate

(R)-5-(3,5-dimethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-5-(2,5-dimethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide

(R)-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid

(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid

(R)-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid

(R)-methyl 2-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate

(R)-methyl 4-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate

(R)-2-fluoro-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

(R)-2-(3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid

(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid

(R)-2-hydroxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

(R)-tert-butyl 3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate

(R)-2-amino-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-N,N,N-trimethylethanaminium hydroxide

5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid

2-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2-methylpropanoic acid

5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid

N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-(3-propoxyphenyl)furan-2-carboxamide

2-(2-fluoro-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid

4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid

5-(3-ethoxy-5-hydroxyphenyl)-N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide

(S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(S)-2-(2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetamido)succinic acid

2-(3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)propanoic acid

(S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(R)-2,6-difluoro-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

3-ethoxy-5-(5-(((3-(N-hydroxyformamido)propanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

1-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)cyclopropanecarboxylic acid

5-ethoxy-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-propoxybenzoic acid

(S)-2-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

(R)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid

2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)acetic acid

2,2'-((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid

2,2'-((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid

5-(3-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamoyl)-5-ethoxyphenyl)-N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide

(R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

(R)-2-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

(R)-2-fluoro-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

(R)-4-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid

(S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid

(3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)(methyl)phosphinic acid

methyl hydrogen (3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl) carbamoyl)furan-2-yl)phenyl)phosphonate

(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid

(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)

carbamoyl) tetrahydrofuran-2-yl)phenyl)phosphonic acid
(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)phosphonic acid
((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid
methyl hydrogen (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido) methyl)carbamoyl)furan-2-yl)phenyl)phosphonate
(R)-5-(3-(2,2-difluoroethoxy)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide
(R)-5-(3-(ethylthio)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl) furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(methylthio)phenyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-nitrophenyl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(1-methyl-1H-indazol-6-yl)furan-2-carboxamide
(R)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-methyl-2H-indazol-6-yl)furan-2-carboxamide
(R)-(3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
5-(3-((Z)-N'-hydroxycarbamimidoyl)phenyl)-N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido) methyl)furan-2-carboxamide and
N-(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-phenyltetrahydrofuran-2-carboxamide;

or a pharmaceutically acceptable salt thereof.

2. A compound selected from the group consisting of:
(3-ethoxy-2-fluoro-5-(5-((((R)-2-((R)-1-(N-

hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
3-hydroxy-5-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
2-(carboxymethyl)-4-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
5-ethoxy-2-hydroxy-3-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-
phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(S)-2-(2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-(2-(naphthalen-2-
yl)ethyl)pentanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
5-(carboxymethoxy)-3-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-
hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-2-hydroxybenzoic acid
(S)-2-(4-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-
yl)benzamido)succinic acid
(S)-2-(4-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-
methylbenzamido)succinic acid
5-(carboxymethoxy)-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
2,2'-((3-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-
hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-5-
ethoxybenzoyl)azanediyl)diacetic acid
(S)-2-(4-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-
hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-2-
ethoxybenzamido)succinic acid
2,2'-((2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-
phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid
(S)-2-(3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-
yl)benzamido)succinic acid
(S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-
hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-
yl)benzamido)succinic acid
(S)-2-(2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-

phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
2-ethoxy-6-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phthalic acid
2-((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)(methyl)amino)acetic acid
3-(2-amino-2-oxoethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(R)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
((R)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
(S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid
(S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid
2,2'-((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid
(((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)amino)methyl)phosphonic acid,
(3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid
(3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid

(3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-(2-(naphthalen-2-yl)ethyl)pentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
((2-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid
((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid
((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzamido)methyl)phosphonic acid
2-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-phosphonophenoxy)acetic acid and
2-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid;


or a pharmaceutically acceptable salt thereof.

3. A compound selected from the group consisting of:
2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzoic acid
3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoic acid
(S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid
(S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
5-ethoxy-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-

hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid
3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid
(S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
(S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid
4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phthalic acid
(3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid
((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid and
(3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid;

or a pharmaceutically acceptable salt thereof.


4. A compound which is (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid



5. A pharmaceutically acceptable salt of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid.


6. A meglumine salt, Tris salt, or calcium salt of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid.

7. A compound which is (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid



8. A pharmaceutically acceptable salt of (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid.

9. A compound which is (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid



10. A pharmaceutically acceptable salt of (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid.

11. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1, and one or more pharmaceutically acceptable excipients.

12. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 2, and one or more pharmaceutically acceptable excipients.

13. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 3, and one or more pharmaceutically acceptable excipients.

14. A pharmaceutical composition comprising (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

15. A pharmaceutical composition comprising (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

16. A pharmaceutical composition comprising (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

17. A compound or pharmaceutically acceptable salt thereof according to any of claims 1-3, for use in therapy.

18. Use of the compound, or pharmaceutically acceptable salt thereof, according to claim 1 in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system.

19. Use of the compound, or pharmaceutically acceptable salt thereof, according to claim 2 in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system.

20. Use of the compound, or pharmaceutically acceptable salt thereof, according to claim 3 in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system.

21. Use of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system.

22. Use of (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system.

23. Use of (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system.

24. Use of the compound, or pharmaceutically acceptable salt thereof, according to claim 1 in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from muscular diseases characterized by reduced muscle function and/or mass.

25. Use of the compound, or pharmaceutically acceptable salt thereof, according to claim 2 in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from muscular diseases characterized by reduced muscle function and/or mass.

26. Use of the compound, or pharmaceutically acceptable salt thereof, according to claim 3 in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from muscular diseases characterized by reduced muscle function and/or mass.

27. Use of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from muscular diseases characterized by reduced muscle function and/or mass.

28. Use of (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from muscular diseases characterized by reduced muscle function and/or mass.

29. Use of (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from muscular diseases characterized by reduced muscle function and/or mass.

30. The use according to any one of claims 18-23, wherein the disease is selected from: myocardial infarction, heart failure, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, cardiac arrhythmia, atrial fibrillation, hypertrophic cardiomyopathy, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, diabetic nephropathy, post-acute kidney injury, chronic kidney disease, delayed graft function post-kidney transplantation, liver cirrhosis, non-alcoholic steatohepatitis, glaucoma, corneal scarring, muscular dystrophy, Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal

muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, keloids, wound healing, adhesions, hypertrophic scarring, scarring, scarring associated with burns, surgery or other trauma, stroke, collagen vascular diseases, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, spinal cord injury, and multiple sclerosis.

31. The use according to any one of claims 24-29, wherein the muscular disease is selected from: muscular dystrophy, Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, sarcopenia, and cachexia associated with heart failure, chronic kidney disease, chronic obstructive pulmonary disease, cancer, or old age.

32. A composition comprising a) the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-3; and b) a combination partner.

33. A composition comprising a) (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

34. A composition comprising a) (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

35. A composition comprising a) (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

36. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-3 either:
a) in the manufacture of a medicament to be used with a combination partner; or
b) together with a combination partner in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the

heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system, and muscular diseases characterized by reduced muscle function and/or mass.

37. Use of the compound (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid, or a pharmaceutically acceptable salt thereof either:
a) in the manufacture of a medicament to be used with a combination partner; or
b) together with a combination partner in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system, and muscular diseases characterized by reduced muscle function and/or mass.

38. Use of the compound (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid, or a pharmaceutically acceptable salt thereof either:
a) in the manufacture of a medicament to be used with a combination partner; or
b) together with a combination partner in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system, and muscular diseases characterized by reduced muscle function and/or mass.

39. Use of the compound (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid, or a pharmaceutically acceptable salt thereof either:
a) in the manufacture of a medicament to be used with a combination partner; or
b) together with a combination partner in the manufacture of a medicament for the treatment of a disease associated with BMP1, TLL1 and/or TLL2 activity; wherein the disease is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system, and muscular diseases characterized by reduced muscle function and/or mass.

40. A combination of a) the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-3; and b) a combination partner.

41. A combination of a) (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid or a pharmaceutically acceptable salt thereof; and b) a combination partner.

42. A combination of a) (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.

43. A combination of a) (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid or a pharmaceutically acceptable salt thereof, and b) a combination partner.